Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 6/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25890301 | 0.84 | FPR2 (0.56) | GHSRFPR2FAAHBDKRB1TRPV1 | |
| SCHEMBL1421040 | 0.83 | NAMPT (0.48) | PSMB8NAMPTCYP17A1 | |
| SCHEMBL25890219 | 0.83 | GHSR (0.44) | GHSRFPR2FAAHBDKRB1TRPV1 | |
| SCHEMBL25890386 | 0.82 | ALDH1A1 (0.47) | GHSR | |
| SCHEMBL25890393 | 0.78 | FPR2 (0.41) | GHSRFPR2FAAHBDKRB1TRPV1 | |
| SCHEMBL31654381 | 0.78 | FPR2 (0.41) | GHSRFPR2FAAHBDKRB1TRPV1 | |
| SCHEMBL19033765 | 0.77 | GHSR (0.53) | GHSRFAAHTRPV1PSMB8CYP17A1 | |
| SCHEMBL31611248 | 0.77 | NAMPT (0.57) | GHSRFPR2NAMPT | |
| SCHEMBL26318454 | 0.77 | NAMPT (0.57) | GHSRFPR2NAMPT | |
| SCHEMBL6235125 | 0.76 | FAAH (0.56) | GHSRFPR2FAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | GHSR 608/4885FPR2 2179/4885FAAH 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.